12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AMR101 regulatory update

Amarin said FDA informed the company that the agency will not schedule an advisory committee meeting to discuss...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >